Overview

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of California, San Diego
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Alprazolam
Anti-Anxiety Agents
Criteria
Inclusion Criteria:

- Male, or female (not pregnant or intending to become pregnant during the study)

- Between the ages of 18-30.

- In good general health.

- No specific contraindications to the drug being administered

Exclusion Criteria:

- Subjects with a history of DSM-IV depressive disorder, psychotic disorder, anxiety
disorder

- Subjects who meet criteria for substance abuse or dependence within the last 6 months

- Subjects with an positive urine screen for illicit drugs

- having clinically significant abnormal laboratory, ECG or physical examination
findings not resolved by the baseline visit

- Patients who have taken psychotropic drugs or antidepressants (including monoamine
oxidase inhibitors, MAOI's) within the last year

- subject is left-handed.

- The subject suffers from claustrophobia, or phobia for injections or blood.

- Magnetic Resonance Imaging related exclusion criteria: cardiac pacemaker, metal
fragments in eyes/skin/body (shrapnel), subjects who have ever been a metal
worker/welder; history of eye surgery/eyes washed out because of metal,
aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid,
heart valve replacement, subjects who are in the first trimester of pregnancy,
subjects with an I.U.D. (birth control device), a shunt (ventricular or spinal),
electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit).